These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 19526525

  • 1. MDM2 SNP309 genotype influences survival of metastatic but not of localized neuroblastoma.
    Perfumo C, Parodi S, Mazzocco K, Defferrari R, Inga A, Scarrà GB, Ghiorzo P, Haupt R, Tonini GP, Fronza G.
    Pediatr Blood Cancer; 2009 Oct; 53(4):576-83. PubMed ID: 19526525
    [Abstract] [Full Text] [Related]

  • 2. Impact of MDM2 SNP309 genotype on progression and survival of stage 4 neuroblastoma.
    Perfumo C, Parodi S, Mazzocco K, Defferrari R, Inga A, Haupt R, Fronza G, Tonini GP.
    Eur J Cancer; 2008 Nov; 44(17):2634-9. PubMed ID: 18835771
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Impact of a single nucleotide polymorphism in the MDM2 gene on neuroblastoma development and aggressiveness: results of a pilot study on 239 patients.
    Cattelani S, Defferrari R, Marsilio S, Bussolari R, Candini O, Corradini F, Ferrari-Amorotti G, Guerzoni C, Pecorari L, Menin C, Bertorelle R, Altavista P, McDowell HP, Boldrini R, Dominici C, Tonini GP, Raschellà G, Calabretta B.
    Clin Cancer Res; 2008 Jun 01; 14(11):3248-53. PubMed ID: 18519749
    [Abstract] [Full Text] [Related]

  • 5. Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors.
    Chien WP, Wong RH, Cheng YW, Chen CY, Lee H.
    Ann Surg Oncol; 2010 Apr 01; 17(4):1194-202. PubMed ID: 19941079
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
    Hirata H, Hinoda Y, Kikuno N, Kawamoto K, Suehiro Y, Tanaka Y, Dahiya R.
    Clin Cancer Res; 2007 Jul 15; 13(14):4123-9. PubMed ID: 17634539
    [Abstract] [Full Text] [Related]

  • 8. MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL.
    Dong HJ, Fang C, Fan L, Zhu DX, Wang DM, Zhu HY, Zhuang Y, Miao KR, Liu P, Xu W, Li JY.
    Int J Cancer; 2012 May 01; 130(9):2054-61. PubMed ID: 21647873
    [Abstract] [Full Text] [Related]

  • 9. MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.
    Gryshchenko I, Hofbauer S, Stoecher M, Daniel PT, Steurer M, Gaiger A, Eigenberger K, Greil R, Tinhofer I.
    J Clin Oncol; 2008 May 10; 26(14):2252-7. PubMed ID: 18467716
    [Abstract] [Full Text] [Related]

  • 10. Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group.
    Schneiderman J, London WB, Brodeur GM, Castleberry RP, Look AT, Cohn SL.
    J Clin Oncol; 2008 Feb 20; 26(6):913-8. PubMed ID: 18281664
    [Abstract] [Full Text] [Related]

  • 11. MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells.
    Slack AD, Chen Z, Ludwig AD, Hicks J, Shohet JM.
    Cancer Res; 2007 Mar 15; 67(6):2448-55. PubMed ID: 17363562
    [Abstract] [Full Text] [Related]

  • 12. Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer.
    Han JY, Lee GK, Jang DH, Lee SY, Lee JS.
    Cancer; 2008 Aug 15; 113(4):799-807. PubMed ID: 18618574
    [Abstract] [Full Text] [Related]

  • 13. Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival.
    Toffoli G, Biason P, Russo A, De Mattia E, Cecchin E, Hattinger CM, Pasello M, Alberghini M, Ferrari C, Scotlandi K, Picci P, Serra M.
    Clin Cancer Res; 2009 May 15; 15(10):3550-6. PubMed ID: 19451596
    [Abstract] [Full Text] [Related]

  • 14. Risk of MDM2 SNP309 alone or in combination with the p53 codon 72 polymorphism in acute myeloid leukemia.
    Xiong X, Wang M, Wang L, Liu J, Zhao X, Tian Z, Wang J.
    Leuk Res; 2009 Nov 15; 33(11):1454-8. PubMed ID: 19423162
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome.
    Falk IJ, Willander K, Chaireti R, Lund J, Nahi H, Hermanson M, Gréen H, Lotfi K, Söderkvist P.
    Eur J Haematol; 2015 Apr 15; 94(4):355-62. PubMed ID: 25156865
    [Abstract] [Full Text] [Related]

  • 17. New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN status.
    Simon T, Spitz R, Faldum A, Hero B, Berthold F.
    J Pediatr Hematol Oncol; 2004 Dec 15; 26(12):791-6. PubMed ID: 15591897
    [Abstract] [Full Text] [Related]

  • 18. Mdm2 Snp309 G allele displays high frequency and inverse correlation with somatic P53 mutations in hepatocellular carcinoma.
    Acun T, Terzioğlu-Kara E, Konu O, Ozturk M, Yakicier MC.
    Mutat Res; 2010 Feb 03; 684(1-2):106-8. PubMed ID: 19954744
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The role of a single nucleotide polymorphism of MDM2 in glioblastoma multiforme.
    Khatri RG, Navaratne K, Weil RJ.
    J Neurosurg; 2008 Nov 03; 109(5):842-8. PubMed ID: 18976073
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.